uniQure N.V. $QURE Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. trimmed its position in uniQure N.V. (NASDAQ:QURE) by 36.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,149,351 shares of the biotechnology company’s stock after selling 658,334 shares during the period. JPMorgan Chase & Co.’s holdings in uniQure were worth $67,088,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Private Trust Co. NA acquired a new stake in shares of uniQure in the 3rd quarter worth $28,000. Jones Financial Companies Lllp raised its holdings in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in uniQure by 358.0% in the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,538 shares during the period. Teacher Retirement System of Texas acquired a new stake in uniQure in the second quarter valued at about $151,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in uniQure in the 2nd quarter valued at approximately $215,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Buying and Selling at uniQure

In other uniQure news, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the transaction, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares in the company, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 4.79% of the company’s stock.

uniQure Stock Performance

NASDAQ QURE opened at $24.03 on Wednesday. The business has a 50 day moving average price of $23.72 and a 200 day moving average price of $29.70. The company has a market capitalization of $1.50 billion, a P/E ratio of -5.47 and a beta of 0.66. uniQure N.V. has a 1-year low of $7.76 and a 1-year high of $71.50. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Scheduled catalyst — uniQure will report Q4 and full‑year 2025 results before the market opens on March 2, 2026 and host a conference call; this gives investors a near‑term event to reassess revenue, expenses and guidance. uniQure to Announce 2025 Financial Results
• Neutral Sentiment: Analyst initiation — Wolfe Research initiated coverage of uniQure with a “peer perform” (market/sector‑perform) rating, which is neutral and unlikely to provide a strong near‑term positive catalyst. Wolfe Research initiates coverage
• Negative Sentiment: Multiple law firms have filed or are soliciting lead plaintiffs for securities class actions covering the September 24–October 31, 2025 period; increased litigation risk typically depresses sentiment and can pressure the stock. Example notices from Kessler Topaz and others were published today. QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP
• Negative Sentiment: Additional plaintiff‑firm solicitations/press releases (Rosen, Pomerantz, Faruqi & Faruqi, Schall, Berger Montague, Gross, Levi & Korsinsky, DJS, etc.) amplify legal headlines and may deter institutional buyers until legal exposure is clearer. ROSEN encourages investors to secure counsel
• Negative Sentiment: The volume of notices and the April 13, 2026 lead‑plaintiff deadline being highlighted across firms creates headline risk; even without merits assessed, investor uncertainty from potential settlements, legal costs or management distraction can weigh on share price. Pomerantz investor alert

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Chardan Capital reiterated a “buy” rating and issued a $53.00 price objective on shares of uniQure in a research report on Thursday, December 4th. Royal Bank Of Canada decreased their target price on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research report on Monday, November 3rd. Finally, The Goldman Sachs Group lowered their price target on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $58.33.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.